Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review.

Tytuł:
Epigenetic Mechanisms in Type 2 Diabetes Retinopathy: A Systematic Review.
Autorzy:
Milluzzo A; Department of Clinical and Experimental Medicine, Endocrinology Section, University of Catania Medical School, 95122 Catania, Italy.; Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia', University of Catania, Via S. Sofia 87, 95123 Catania, Italy.
Maugeri A; Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia', University of Catania, Via S. Sofia 87, 95123 Catania, Italy.
Barchitta M; Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia', University of Catania, Via S. Sofia 87, 95123 Catania, Italy.
Sciacca L; Department of Clinical and Experimental Medicine, Endocrinology Section, University of Catania Medical School, 95122 Catania, Italy.
Agodi A; Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia', University of Catania, Via S. Sofia 87, 95123 Catania, Italy.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Sep 28; Vol. 22 (19). Date of Electronic Publication: 2021 Sep 28.
Typ publikacji:
Journal Article; Systematic Review
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
DNA Methylation*
Epigenesis, Genetic*
Promoter Regions, Genetic*
Diabetes Mellitus, Type 2/*metabolism
Diabetic Retinopathy/*metabolism
Methylenetetrahydrofolate Reductase (NADPH2)/*biosynthesis
MicroRNAs/*biosynthesis
RNA, Long Noncoding/*biosynthesis
Diabetes Mellitus, Type 2/genetics ; Diabetes Mellitus, Type 2/pathology ; Diabetic Retinopathy/genetics ; Diabetic Retinopathy/pathology ; Humans ; Methylenetetrahydrofolate Reductase (NADPH2)/genetics ; MicroRNAs/genetics ; RNA, Long Noncoding/genetics
References:
Diabetes Metab Res Rev. 2019 Mar;35(3):e3113. (PMID: 30548967)
Ophthalmology. 1991 May;98(5 Suppl):786-806. (PMID: 2062513)
J Cell Mol Med. 2019 Feb;23(2):1280-1287. (PMID: 30467971)
Med Sci Monit. 2019 Nov 11;25:8509-8514. (PMID: 31711064)
Sci Rep. 2018 Apr 25;8(1):6526. (PMID: 29695738)
Eur J Med Genet. 2015 Jan;58(1):1-10. (PMID: 25449138)
BMC Mol Cell Biol. 2019 Aug 27;20(1):39. (PMID: 31455213)
Arch Soc Esp Oftalmol. 2016 May;91(5):209-16. (PMID: 26948458)
Diabetol Metab Syndr. 2019 Jan 15;11:4. (PMID: 30675189)
Diabetes Care. 2011 Apr;34(4):968-74. (PMID: 21447665)
Bosn J Basic Med Sci. 2020 Aug 03;20(3):365-371. (PMID: 31999937)
Am J Physiol Endocrinol Metab. 2018 Sep 1;315(3):E374-E385. (PMID: 29812988)
Med Sci Monit. 2018 Sep 01;24:6079-6084. (PMID: 30171178)
PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072)
Biochem Biophys Res Commun. 2009 Mar 27;381(1):81-3. (PMID: 19351599)
Front Endocrinol (Lausanne). 2017 Sep 29;8:237. (PMID: 29085333)
Eur Rev Med Pharmacol Sci. 2015;19(11):2010-5. (PMID: 26125263)
IUBMB Life. 2019 Mar;71(3):310-320. (PMID: 30468285)
Diabetes Care. 2009 Dec;32(12):2307-13. (PMID: 19940227)
Liver Int. 2019 Sep;39(9):1742-1754. (PMID: 31169972)
Biosci Rep. 2017 Mar 27;37(2):. (PMID: 28108673)
Indian J Ophthalmol. 2012 Sep-Oct;60(5):387-95. (PMID: 22944747)
Diabetol Metab Syndr. 2017 Oct 18;9:84. (PMID: 29075332)
Clin Exp Ophthalmol. 2019 Sep;47(7):925-936. (PMID: 31081578)
J Endocrinol Invest. 2017 Jun;40(6):591-610. (PMID: 28213644)
Nat Biotechnol. 2010 Oct;28(10):1057-68. (PMID: 20944598)
J Diabetes Complications. 2020 Jul;34(7):107604. (PMID: 32360194)
Ophthalmology. 2015 Jul;122(7):1375-94. (PMID: 25935789)
Meta Gene. 2015 Oct 22;6:91-5. (PMID: 26629414)
J Diabetes Complications. 2018 Jun;32(6):593-601. (PMID: 29674133)
Diabetes Res Clin Pract. 2017 Nov;133:21-29. (PMID: 28888147)
J Diabetes Res. 2020 Oct 14;2020:9036847. (PMID: 33123599)
Diabetes Metab Res Rev. 2015 Feb;31(2):183-9. (PMID: 25069700)
Cell Physiol Biochem. 2014;34(5):1733-40. (PMID: 25427542)
PLoS One. 2011 Apr 22;6(4):e19139. (PMID: 21544242)
J Clin Med. 2019 Dec 15;8(12):. (PMID: 31847440)
Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):535-40. (PMID: 14991334)
Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):941-51. (PMID: 24436191)
Graefes Arch Clin Exp Ophthalmol. 2019 Sep;257(9):1897-1913. (PMID: 31327036)
N Engl J Med. 2012 Mar 29;366(13):1227-39. (PMID: 22455417)
PLoS One. 2020 Apr 13;15(4):e0231196. (PMID: 32282852)
Dev Cell. 2008 Aug;15(2):261-71. (PMID: 18694565)
Br J Ophthalmol. 2006 Nov;90(11):1404-9. (PMID: 16825278)
PLoS One. 2016 Jun 28;11(6):e0158043. (PMID: 27351379)
Clinics (Sao Paulo). 2017 Feb 01;72(2):111-115. (PMID: 28273235)
Diabetologia. 2001 Feb;44(2):156-63. (PMID: 11270671)
Cell Death Dis. 2014 Oct 30;5:e1506. (PMID: 25356875)
Diabetologia. 1994 Mar;37(3):278-85. (PMID: 8174842)
Acta Diabetol. 2017 Feb;54(2):133-139. (PMID: 27696070)
Acta Ophthalmol. 2011 Aug;89(5):405-11. (PMID: 21294854)
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1159-1166. (PMID: 28382439)
Front Physiol. 2020 Jan 29;10:1621. (PMID: 32063865)
Epigenetics. 2012 Aug;7(8):841-52. (PMID: 22810088)
Bull World Health Organ. 2004 Nov;82(11):844-51. (PMID: 15640920)
Diabetes Res Clin Pract. 2011 Jan;91(1):94-100. (PMID: 21146880)
Int J Ophthalmol. 2018 Dec 18;11(12):1889-1894. (PMID: 30588418)
Antioxid Redox Signal. 2017 Nov 1;27(13):913-930. (PMID: 28173719)
Clin Exp Med. 2019 May;19(2):255-260. (PMID: 30673918)
Cardiovasc Diabetol. 2021 Jul 16;20(1):145. (PMID: 34271948)
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4090-8. (PMID: 26114486)
Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):335-42. (PMID: 24970617)
IUBMB Life. 2016 Jun;68(6):452-8. (PMID: 27118517)
Diabetes. 2009 Dec;58(12):2718-25. (PMID: 19940235)
Diabetes Res Clin Pract. 2018 Jun;140:228-235. (PMID: 29625141)
Clin Exp Med. 2019 Nov;19(4):469-477. (PMID: 31422516)
Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):607-13. (PMID: 25753878)
Cell Physiol Biochem. 2018;50(3):1005-1014. (PMID: 30355913)
Cell Biosci. 2017 Aug 15;7:42. (PMID: 28815013)
Contributed Indexing:
Keywords: DNA methylation; diabetes complications; epigenetic; lnc-RNA; miRNA; retinopathy; type 2 diabetes
Substance Nomenclature:
0 (MicroRNAs)
0 (RNA, Long Noncoding)
EC 1.5.1.20 (MTHFR protein, human)
EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
Entry Date(s):
Date Created: 20211013 Date Completed: 20211026 Latest Revision: 20211026
Update Code:
20240105
PubMed Central ID:
PMC8509039
DOI:
10.3390/ijms221910502
PMID:
34638838
Czasopismo naukowe
Diabetic retinopathy (DR) is one of the main causes of vision loss in middle-aged economically active people. Modifiable (i.e., hyperglycaemia, hypertension, hyperlipidaemia, obesity, and cigarette smoke) and non-modifiable factors (i.e., duration of diabetes, puberty, pregnancy and genetic susceptibility) are involved in the development of DR. Epigenetic mechanisms, modulating the oxidative stress, inflammation, apoptosis, and aging, could influence the course of DR. Herein, we conducted a systematic review of observational studies investigating how epigenetics affects type 2 diabetes retinopathy (T2DR). A total of 23 epidemiological studies were included: 14 studies focused on miRNA, 4 studies on lnc-RNA, one study on both miRNA and lnc-RNA, and 4 studies on global or gene-specific DNA methylation. A direct relation between the dysregulation of miR-21, miR-93, and miR-221 and FPG, HbA1c, and HOMA-IR was identified. A panel of three miRNAs (hsa-let-7a-5p, hsa-miR-novel-chr5_15976, and hsa-miR-28-3p) demonstrated a good sensitivity and specificity for predicting T2DR. Little evidence is available regarding the possible role of the long non-coding MALAT1 dysregulation and MTHFR gene promoter hypermethylation. Despite these initial, encouraging findings potentially suggesting a role of epigenetics in T2DR, the use in clinical practice for the diagnosis and staging of this complication encounters several difficulties and further targeted investigations are still necessary.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies